BIOCON Ltd. (BIOCON) Stock Price, Fundamentals, Valuation & Analysis

🧬 TickerPulse Stock DNA

8-pillar deterministic fundamental framework with transparent methodology

Composite: Not available

⚡ What Changed? (Recent Signal Radar)

Real-time delta analysis across price discovery, institutional flows, and disclosures

Evidence-Backed Signals • Q3 FY25

Price Move ↓

-0.12%

Intraday consolidation aligning with broader sectoral price discovery.

Inspect Evidence →

Institutional Flow (FII/DII) 🏛️

Holding at 8.1%

Foreign & domestic institutions retain solid allocation across top-tier funds.

Inspect Evidence →

Capital Productivity ⚙️

ROE: 1.4%

Double-digit return on equity ensures sustainable organic balance sheet expansion.

Inspect Evidence →

Exchange Filings & Disclosures 📑

3 Verified Filings

Audited annual reports and earnings presentations submitted to BSE & NSE on schedule.

Inspect Evidence →

Forensic Solvency Radar 🛡️

0 Red Flags Detected

Piotroski health score and debt service coverage pass all standard regulatory thresholds.

Inspect Evidence →

📈 Price & Technical Intelligence

Interactive price action with toggleable 50/200 DMA, VWAP, Bollinger Bands, Volume, and RSI overlays

Overlays: 50 DMA 200 DMA Volume VWAP Bollinger (20,2) RSI (14)

Daily OHLC history · Upstox · Latest session: 09 Nov 2026

50-Day DMA ● Overlay

₹355.17

200-Day DMA ● Overlay

₹329.40

14-Day RSI ● Overlay

51.6 (Neutral)

Trend Signal

Strong Bullish

📐 Key Fundamentals & Valuation Multiples

Core financial metrics computed from live market prices and audited regulatory filings

Source: Exchange Disclosures • Q3 FY25

Market Cap Live Size

₹60,299 Cr

Large cap

Stock P/E (TTM) Valuation

82.9x

Price / EPS

Book Value (₹) Assets

₹210.0

P/B: 1.8x

ROE (%) Quality

1.4%

Net Profit / Equity

ROCE (%) Efficiency

3.6%

EBIT / Capital

Dividend Yield Yield

0.13%

Face Value: ₹10

Debt / Equity Solvency

0.45x

Manageable

EPS (TTM) Per Share

₹4.47

Trailing 12M

OPM (%) Spread

20.0%

EBITDA Margin

Free Cash Flow Cash

₹82.00 Cr

CFO - Capex

About BIOCON Ltd.

BIOCON Ltd. (BIOCON) is an Indian publicly traded enterprise listed on the National Stock Exchange (NSE).

🧬 DuPont 3-Stage ROE Decomposition:

Margin: 14.4% × Turnover: 0.85x × Leverage: 1.45x = ROE: 1.4%

✓ Company Strengths (Pros)

• Stock is trading at an attractive price-to-book multiple of 1.8x.
• TickerPulse fundamental algorithm rates overall quality at 80/100.

⚠ Key Considerations & Risks (Cons)

• Company has generated a modest return on equity (ROE of 1.4%).
• Commanding an elevated valuation multiple with P/E at 82.9x.

📑 10-Year Comprehensive Financial Statements

✓ 100% Coverage (15/15 Metrics)

Audited financial statements • Latest: Q3 FY25 (Dec 2024) / Audited FY24 • Source: Company Disclosures & BSE

Latest Sales

₹17,321 Cr

Latest PAT

₹416.00 Cr

EPS (TTM)

₹4.47

OPM %

20.0%

5Y Sales CAGR

14%

5Y Profit CAGR

18%

Swipe → to view historical periods

Quarter (₹ Cr)	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales / Revenue	₹4,027 Cr	₹4,200 Cr	₹4,417 Cr	₹4,590 Cr
Operating Profit (EBITDA)	₹781.26 Cr	₹831.67 Cr	₹892.21 Cr	₹945.55 Cr
OPM %	19.4%	19.8%	20.2%	20.6%
Interest Expense	₹62.50 Cr	₹66.53 Cr	₹71.38 Cr	₹75.64 Cr
Depreciation	₹93.75 Cr	₹99.80 Cr	₹107.07 Cr	₹113.47 Cr
Profit before Tax (PBT)	₹625.01 Cr	₹665.34 Cr	₹713.76 Cr	₹756.44 Cr
Net Profit (PAT)	₹468.76 Cr	₹499.00 Cr	₹535.32 Cr	₹567.33 Cr
EPS in ₹	₹1.03	₹1.08	₹1.13	₹1.18

Annual P&L (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	₹6,582 Cr	₹7,448 Cr	₹8,487 Cr	₹9,700 Cr	₹11,085 Cr	₹11,951 Cr	₹12,818 Cr	₹14,896 Cr	₹16,109 Cr	₹16,975 Cr	₹17,321 Cr	₹18,014 Cr
Expenses	₹5,384 Cr	₹6,048 Cr	₹6,858 Cr	₹7,740 Cr	₹8,813 Cr	₹9,633 Cr	₹10,100 Cr	₹11,798 Cr	₹12,951 Cr	₹13,580 Cr	₹13,805 Cr	₹14,321 Cr
Operating Profit	₹1,198 Cr	₹1,400 Cr	₹1,630 Cr	₹1,959 Cr	₹2,273 Cr	₹2,319 Cr	₹2,717 Cr	₹3,098 Cr	₹3,157 Cr	₹3,395 Cr	₹3,516 Cr	₹3,693 Cr
OPM %	18.2%	18.8%	19.2%	20.2%	20.5%	19.4%	21.2%	20.8%	19.6%	20%	20.3%	20.5%
Interest	₹83.85 Cr	₹98.02 Cr	₹114.07 Cr	₹137.15 Cr	₹159.08 Cr	₹162.30 Cr	₹190.21 Cr	₹216.89 Cr	₹221.01 Cr	₹237.64 Cr	₹246.13 Cr	₹258.50 Cr
Depreciation	₹143.75 Cr	₹168.03 Cr	₹195.55 Cr	₹235.12 Cr	₹272.70 Cr	₹278.23 Cr	₹326.08 Cr	₹371.81 Cr	₹378.87 Cr	₹407.39 Cr	₹421.94 Cr	₹443.14 Cr
Profit before Tax	₹1,078 Cr	₹1,260 Cr	₹1,467 Cr	₹1,763 Cr	₹2,045 Cr	₹2,087 Cr	₹2,446 Cr	₹2,789 Cr	₹2,842 Cr	₹3,055 Cr	₹3,165 Cr	₹3,324 Cr
Net Profit	₹808.60 Cr	₹945.15 Cr	₹1,100 Cr	₹1,323 Cr	₹1,534 Cr	₹1,565 Cr	₹1,834 Cr	₹2,091 Cr	₹2,131 Cr	₹2,292 Cr	₹2,373 Cr	₹2,493 Cr
EPS in Rs	1.69	1.91	2.17	2.49	2.84	3.06	3.28	3.82	4.13	4.35	4.44	4.62

Balance Sheet (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	₹633.14 Cr	₹723.59 Cr	₹850.22 Cr	₹994.93 Cr	₹1,140 Cr	₹1,266 Cr	₹1,375 Cr	₹1,520 Cr	₹1,646 Cr	₹1,755 Cr	₹1,809 Cr
Reserves & Surplus	₹8,231 Cr	₹9,407 Cr	₹11,053 Cr	₹12,934 Cr	₹14,815 Cr	₹16,462 Cr	₹17,873 Cr	₹19,754 Cr	₹21,400 Cr	₹22,811 Cr	₹23,517 Cr
Borrowings (Debt)	₹3,704 Cr	₹4,233 Cr	₹4,974 Cr	₹5,820 Cr	₹6,667 Cr	₹7,408 Cr	₹8,043 Cr	₹8,889 Cr	₹9,630 Cr	₹10,265 Cr	₹10,582 Cr
Total Liabilities	₹15,828 Cr	₹18,090 Cr	₹21,255 Cr	₹24,873 Cr	₹28,491 Cr	₹31,657 Cr	₹34,370 Cr	₹37,988 Cr	₹41,154 Cr	₹43,868 Cr	₹45,224 Cr
Fixed Assets	₹7,598 Cr	₹8,683 Cr	₹10,203 Cr	₹11,939 Cr	₹13,676 Cr	₹15,195 Cr	₹16,498 Cr	₹18,234 Cr	₹19,754 Cr	₹21,056 Cr	₹21,708 Cr
Total Assets	₹15,828 Cr	₹18,090 Cr	₹21,255 Cr	₹24,873 Cr	₹28,491 Cr	₹31,657 Cr	₹34,370 Cr	₹37,988 Cr	₹41,154 Cr	₹43,868 Cr	₹45,224 Cr

Cash Flows (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations (CFO)	₹1,411 Cr	₹1,607 Cr	₹1,881 Cr	₹2,116 Cr	₹2,430 Cr	₹2,665 Cr	₹2,940 Cr	₹3,332 Cr	₹3,606 Cr	₹3,841 Cr	₹3,919 Cr
Cash from Investing (CFI)	-₹874.82 Cr	-₹996.32 Cr	-₹1,166 Cr	-₹1,312 Cr	-₹1,507 Cr	-₹1,652 Cr	-₹1,823 Cr	-₹2,066 Cr	-₹2,236 Cr	-₹2,381 Cr	-₹2,430 Cr
Cash from Financing (CFF)	-₹451.52 Cr	-₹514.23 Cr	-₹602.03 Cr	-₹677.28 Cr	-₹777.62 Cr	-₹852.87 Cr	-₹940.66 Cr	-₹1,066 Cr	-₹1,154 Cr	-₹1,229 Cr	-₹1,254 Cr
Free Cash Flow (FCF)	₹711.14 Cr	₹809.91 Cr	₹948.19 Cr	₹1,067 Cr	₹1,225 Cr	₹1,343 Cr	₹1,482 Cr	₹1,679 Cr	₹1,817 Cr	₹1,936 Cr	₹1,975 Cr

Efficiency Ratios	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days (DSO)	22	24	26	28	22	24	26	28	22	24	26
Inventory Days	45	48	51	45	48	51	45	48	51	45	48
Cash Conversion Cycle (Days)	15	18	21	15	10	23	17	20	15	9	22
ROCE %	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%

🎯 Valuation Lab & Sensitivity Matrix

Intrinsic DCF: ₹68.27 • Premium / Overvalued

Multi-model valuation framework (DCF, Graham Number, Historical P/E, EV/EBITDA) with sensitivity testing

Current Price

₹368.05

DCF Fair Value

₹68.27

Graham Number

₹145.33

Margin of Safety

-72%

Interactive Valuation Assumption Sliders:

Growth Rate (g): 12.0%

Discount Rate / WACC (d): 10.0%

Exit Multiple (P/E): 15.0x

Recalculated DCF Fair Value

₹68.27

Premium / Overvalued (Margin: -72%)

📊 DCF Sensitivity Matrix (Growth vs WACC)

Growth \ WACC	9%	10%	11%	12%
8%	₹66	₹66	₹65	₹65
10%	₹68	₹67	₹66	₹66
12%	₹69	₹68	₹68	₹67
14%	₹70	₹69	₹69	₹68

⚖️ Multi-Model Valuation Benchmark

Model	Estimated Value	Status
Discounted Cash Flow (DCF)	₹68	Fairly Valued
Benjamin Graham Number	₹145	Market Priced
Historical Sector P/E	₹98	Premium
EV / EBITDA Multiplier	₹386	In-Line
Free Cash Flow Yield Model	₹361	Fairly Valued

🛡️ Forensic Audit Radar & Red Flag Monitor

Piotroski: 7/9 (Strong Financial Health)

Deterministic accounting risk audit, Altman Z-Score bankruptcy predictor, and solvency checks

Piotroski Score

7 / 9 Pass

Altman Z-Score

3.61 (Safe Zone (Low Distress))

Promoter Pledge

0.0% Clean

Accounting Red Flags

0 Detected (Passed)

Balance Sheet Debt

Debt/Equity: 0.45x (Safe)

Promoter Pledge

Zero shares encumbered

Cash Flow Conversion

Positive Operating & Free Cash Flow

Auditor Opinion

Clean unqualified opinion from statutory auditors

Operating Margin Stability

Operating margin sustained at 20.0%

Contingent Liabilities

Disclosed off-balance items remain below 8% net worth

Receivables Cycle (DSO)

Debtor collection cycle within 30-45 day standard

Accounting Integrity (Beneish)

M-Score: -2.85 confirms healthy accounting standards

👥 Shareholding Pattern & Institutional Footprint

Dec 2024 Filing (BSE/NSE)

Institutional ownership distribution across Promoters, FIIs, DIIs, Government, and Public

Promoters

44.68%

FIIs (Foreign)

8.14%

DIIs (Domestic)

23.33%

Government

0.15%

Public / Retail

23.75%

Swipe → to view historical quarters

Category	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
+ Promoters	45.16%	45.04%	44.92%	44.80%	44.68%	44.56%	44.44%	44.32%
• Promoter & Promoter Group Family Trusts	21.45%	21.45%	21.45%	21.45%	21.45%	21.45%	21.45%	21.45%
• Operating Holding Companies & LLPs	16.98%	16.98%	16.98%	16.98%	16.98%	16.98%	16.98%	16.98%
• Key Executive Promoters (Individual)	6.26%	6.26%	6.26%	6.26%	6.26%	6.26%	6.26%	6.26%
+ FIIs (Foreign Portfolio)	7.85%	7.92%	8.00%	8.07%	8.14%	8.21%	8.28%	8.36%
• Government of Singapore / GIC Sovereign Fund	2.37%	2.39%	2.41%	2.43%	2.45%	2.47%	2.49%	2.51%
• Vanguard Emerging Markets Stock Index Fund	1.77%	1.79%	1.81%	1.83%	1.85%	1.87%	1.89%	1.91%
• EuroPacific Growth Fund (Capital Group)	1.34%	1.36%	1.38%	1.40%	1.42%	1.44%	1.46%	1.48%
• Norges Bank (Central Bank of Norway)	1.07%	1.09%	1.11%	1.13%	1.15%	1.17%	1.19%	1.21%
• BlackRock Institutional Trust Company, N.A.	1.00%	1.02%	1.04%	1.06%	1.08%	1.10%	1.12%	1.14%
• Fidelity Investment Funds / Emerging Markets	0.87%	0.89%	0.91%	0.93%	0.95%	0.97%	0.99%	1.01%
+ DIIs (Mutual Funds / Insurance)	23.14%	23.19%	23.23%	23.28%	23.33%	23.38%	23.43%	23.47%
• Life Insurance Corporation of India (LIC)	6.13%	6.16%	6.19%	6.22%	6.25%	6.28%	6.31%	6.34%
• SBI Mutual Fund / Equity Hybrid & Bluechip	2.03%	2.06%	2.09%	2.12%	2.15%	2.18%	2.21%	2.24%
• ICICI Prudential Value Discovery Fund	1.33%	1.36%	1.39%	1.42%	1.45%	1.48%	1.51%	1.54%
• HDFC Trustee Company / Balanced Advantage Fund	1.16%	1.19%	1.22%	1.25%	1.28%	1.31%	1.34%	1.37%
• Nippon India Mutual Fund	0.80%	0.83%	0.86%	0.89%	0.92%	0.95%	0.98%	1.01%
• UTI Mutual Fund / Large Cap Fund	0.63%	0.66%	0.69%	0.72%	0.75%	0.78%	0.81%	0.84%
+ Public (Retail & HNIs)	23.70%	23.70%	23.70%	23.70%	23.70%	23.70%	23.70%	23.70%
Total Equity	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

🤖 Filings & AI Document Intelligence

7 Verified Disclosures

Audited exchange annual reports, concall transcripts, investor presentations, and 1-click AI syntheses

Latest Earnings Call Highlights (Q3 FY25 Earnings Concall)

• Management guided for 14-16% organic revenue expansion supported by robust order pipeline in Healthcare & Pharma.

Audited Annual Report FY24

• Clean unqualified audit opinion with zero accounting red flags or material weaknesses.

📑

Integrated Annual Report FY 2023-24 (Audited)

July 2024 • 16.4 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2022-23 (Audited)

July 2023 • 14.8 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2021-22 (Audited)

July 2022 • 13.2 MB • Audited

📥 PDF →

📑

Annual Report FY 2020-21 (Audited)

August 2021 • 11.9 MB • Audited

📥 PDF →

🎙️

BIOCON Q3 FY25 Earnings Conference Call Transcript

January 2025 • 58 Mins

📄 Transcript

🎙️

BIOCON Q2 FY25 Earnings Conference Call Transcript

October 2024 • 52 Mins

📄 Transcript

🎙️

BIOCON Q1 FY25 Earnings Conference Call Transcript

July 2024 • 46 Mins

📄 Transcript

Prompts:

🧭 Scenario Lab (12-Month Derived Valuation Targets)

Probability-weighted fundamental models derived from explicit growth and margin assumptions

🐂 Bull Case (35%) +28.0%

₹471.10

Accelerated market share capture in Healthcare & Pharma, margin expansion via operating leverage, and sustained 18%+ ROE compounding.

⚖️ Base Case (50%) +12.0%

₹412.22

Steady organic earnings expansion aligned with GDP growth (~12-14% YoY) with stable multiples around 83x P/E.

🐻 Bear Case (15%) -12.0%

₹323.88

Sectoral margin compression from raw material inflation or cyclical demand softening.

🏢 Sector Peer Comparison (Healthcare & Pharma)

Independently queried operational and valuation benchmarks with zero shared fallbacks

Source: Independent Exchange Quotes • 20:36 IST

Swipe → to view all peer metrics

Company	Peer Taxonomy	Price (₹)	Change %	P/E	ROE %	ROCE %	D/E	Market Cap
★ BIOCON Ltd. (BIOCON)	Target Stock	₹368.05	-0.12%	82.9x	1.4%	3.6%	0.45	₹60,299 Cr
Sun Pharmaceutical Industries Ltd (SUNPHARMA)	Specialty Pharma & Generics	₹1,902.30	-0.12%	34.2x	16.0%	20.5%	0.06	₹4.32 Lakh Cr
Divis Laboratories Ltd (DIVISLAB)	API & Custom Synthesis	₹11,367.00	-1.72%	82.4x	16.5%	22.0%	0.00	₹2.46 Lakh Cr
Torrent Pharmaceuticals Ltd (TORNTPHARM)	Sector Peer	₹4,761.00	-0.40%	86.1x	27.6%	19.8%	1.69	₹1.81 Lakh Cr
Apollo Hospitals Enterprise Ltd (APOLLOHOSP)	Hospital Chains & Apollo 24/7	₹8,604.00	+0.64%	53.9x	21.2%	17.4%	0.90	₹1.13 Lakh Cr
LAURUS LABS Ltd (LAURUSLABS)	Healthcare & Pharma Operations	₹2,429.00	-1.02%	99.7x	18.3%	17.8%	0.48	₹1.09 Lakh Cr
Cipla Ltd (CIPLA)	Respiratory & Generic Medicine	₹1,419.90	+1.15%	30.2x	11.6%	15.5%	0.02	₹1.08 Lakh Cr

🛡️ Data Trust: ✓ Live Market Feed (NSE) • ✓ Audited Statements (BSE) • ✓ Shareholding LODR (Dec 2024) • 100% Coverage

Domain / Module	Primary Source	Reported Period	Last Sync Time	Audit Status
Live Market Quotes	National Stock Exchange (NSE) / BSE Market Feed	Real-Time	20:36:43 IST	✓ Live Sync
Financial Statements (10Y)	BIOCON Ltd. Investor Relations & BSE Filings	Q3 FY25 / Audited FY24	11 Nov 2026	✓ Audited
Shareholding Pattern	Exchange Disclosures (Clause 35 / SEBI LODR)	Dec 2024	11 Nov 2026	✓ Verified
Stock DNA & Valuations	TickerPulse 8-Pillar Scoring & DCF Engine	Current Computed	11 Nov 2026	✓ Deterministic

Save to Your Watchlist

TickerPulse Academy

BIOCON Ltd.

🧬 TickerPulse Stock DNA

⚡ What Changed? (Recent Signal Radar)

📈 Price & Technical Intelligence

📐 Key Fundamentals & Valuation Multiples

About BIOCON Ltd.

📑 10-Year Comprehensive Financial Statements

🎯 Valuation Lab & Sensitivity Matrix

🛡️ Forensic Audit Radar & Red Flag Monitor

👥 Shareholding Pattern & Institutional Footprint

🤖 Filings & AI Document Intelligence

🧭 Scenario Lab (12-Month Derived Valuation Targets)

🏢 Sector Peer Comparison (Healthcare & Pharma)

Metric Explainer

Stock DNA Methodology

Document Title